ProBioGen Signs Next GlymaxX® ADCC Technology Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform
|| Print ||
|Wednesday, 20 February 2013 10:00 (UTC + 1)|
Berlin, Germany, February 20, 2013 / B3C newswire / – Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology. The license covers the modification of the pharma’s antibody production platform for the generation of antibodies with enhanced potency. The continued licensing success demonstrates the industry’s endorsement of GlymaxX®. The GlymaxX® technology is highly versatile since it can be applied to any starter or production cell line. It allows both, the robust permanent modification of established antibody expression platforms, as well as the rapid conversion of existing antibody producer clones to produce ADCC-enhanced molecules.
The GlymaxX® technology is based on the stable expression of a heterologous enzyme in the antibody producing cells. GlymaxX® prevents antibody fucosylation almost completely, but moreover allows the exact adjustment of any desired fucosylation level through the controlled addition of fucose into the culture medium.
The license with an option for a commercial license covers the modification of the company’s antibody production platform and the generation of multiple antibodies with enhanced ADCC potency. Financial details are not disclosed.
The technology can be licensed royalty-free, based on milestone-dependent license fees only.
ProBioGen was founded 1994 and is located in Berlin, Germany.
ProBioGen offers this technology royalty-free as service or as license to third parties.
Dr. Gabriele Schneider